JPMORGAN CHASE & CO - SYNAGEVA BIOPHARMA CORP ownership

SYNAGEVA BIOPHARMA CORP's ticker is GEVA and the CUSIP is 87159A103. A total of 116 filers reported holding SYNAGEVA BIOPHARMA CORP in Q1 2014. The put-call ratio across all filers is 2.05 and the average weighting 0.2%.

Quarter-by-quarter ownership
JPMORGAN CHASE & CO ownership history of SYNAGEVA BIOPHARMA CORP
ValueSharesWeighting
Q1 2015$27,938,000
+31.3%
286,447
+24.9%
0.01%
+20.0%
Q4 2014$21,280,000
+165.7%
229,340
+97.0%
0.01%
+150.0%
Q3 2014$8,008,000
-35.4%
116,431
-1.5%
0.00%
-33.3%
Q2 2014$12,390,000
+31.7%
118,231
+4.3%
0.00%0.0%
Q1 2014$9,408,000
+132.5%
113,401
+81.4%
0.00%
+200.0%
Q4 2013$4,047,000
+562.4%
62,526
+548.7%
0.00%
Q3 2013$611,000
-19.2%
9,638
-46.5%
0.00%
Q2 2013$756,00017,9990.00%
Other shareholders
SYNAGEVA BIOPHARMA CORP shareholders Q1 2014
NameSharesValueWeighting ↓
Baker Brothers Advisors 10,660,432$1,117,213,00013.68%
BB BIOTECH AG 898,476$94,160,0004.47%
SECTORAL ASSET MANAGEMENT INC 516,445$54,123,0002.29%
Ghost Tree Capital, LLC 30,000$3,144,0002.22%
COLUMBIA WANGER ASSET MANAGEMENT LLC 3,521,000$369,001,0001.48%
Pier Capital, LLC 83,493$8,750,0001.24%
ArrowMark Colorado Holdings LLC 197,613$20,710,0000.59%
PALISADE CAPITAL MANAGEMENT, LP 120,779$12,658,0000.31%
FORTALEZA ASSET MANAGEMENT INC/ 5,440$570,0000.26%
Tradeworx Inc. 2,936$308,0000.25%
View complete list of SYNAGEVA BIOPHARMA CORP shareholders